Navigation Links
Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives
Date:12/5/2007

in which we have successfully achieved several major goals," said Edward Lanphier, president and CEO of Sangamo. "The progress that we have made this year in both clinical and business development activities put us in a very strong position to continue to advance and commercialize our ZFP technology in therapeutics, plant agriculture, laboratory reagents and enhanced cell-lines for pharmaceutical protein manufacturing. We expect 2008 to be another year of significant accomplishments for Sangamo as we achieve a number of major value-creating events."

Mr. Lanphier continued, "We presented positive top-line clinical data from our Phase 1b trial of our lead ZFP Therapeutic(TM), SB-509, an activator of vascular endothelial growth factor (VEGF) for the treatment of diabetic neuropathy (DN). Sangamo is building on this positive data by initiating further clinical trials as we continue our efforts to develop this technology as a novel platform for therapeutic development. This year we also achieved our goal of successfully completing the accrual of subjects to the Phase 2 trial of SB-509 for DN which will give us data in the second half of 2008. In addition to our two Phase 2 clinical trials in DN, we have announced our plans to initiate further Phase 2 studies of SB-509 in stem cell mobilization and amyotrophic lateral sclerosis (ALS) and to initiate two Phase 1 clinical trials in ZFP-mediated gene modification for glioblastoma and HIV/AIDS. We have also advanced and expanded our preclinical pipeline and presented data from several programs at major scientific and medical meetings.

"We also continued to monetize our technology outside of the human therapeutic space. This year we established a major relationship with Sigma-Aldrich Corporation to develop and commercialize ZFP-based laboratory research reagents. We also entered into several cell-line engineering collaborations including a commercial license agreement with Genenetech. The research phase of our co
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The family foundation of Best Buy founder, Richard ... Foundation (Meso Foundation), half of which will be specifically ... Program . The focus area of the Richard M. ... organizations that can generate transformational results in education, human ... and chairman emeritus of Best Buy Co., Inc., the ...
(Date:11/26/2014)... Arlington, VA (PRWEB) November 26, 2014 ... Ushma Suvarnakar as the Association’s new director of ... directing the Association’s annual meeting, special events and ... Ushma Suvarnakar to this post,” said AAA Executive ... contagious level of enthusiasm and energy. She was ...
(Date:11/26/2014)... For its December issue , Atlantic Information ... Blue Cross and Blue Shield Plans* interviewed officials at ... the two Blues plans are implementing in order to ... apnea, ranging from brick-and-mortar retail stores to patient data ... rates of a variety of serious disorders, including hypertension, ...
(Date:11/26/2014)... GI for Life announced today, that they ... of their popular nutritional supplements: ColoVite Colon Health ... Discounts of 40% will be offered for a limited ... ColoVite supplement is a scientifically formulated vitamin supplement developed ... easy-to-take colon vitamin with ALL the nutrients associated with ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Anthropologists ... effectiveness in containing and stopping Ebola, improve international ... in healthcare systems in West Africa. , ... to Stop Ebola: Anthropologists Offer Insights,” will be ... the American Anthropological Association (AAA), Fri., Dec. 5, ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
... Karolinska Institutet sheds light on the pathological course of ... to display amyloids demonstrable with a PET scanner has ... after death. One pathological characteristic of Alzheimer,s ... proteins to form amyloid plaques. However, it is not ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Babies born ... of stress hormones, decreased muscle tone and other neurological and ... are that [the infants] are either more sensitive to stress ... less able to shut down their stress response," lead investigator ...
... A one-year follow-up study on seniors who participated in a ... as savings for the healthcare system. The research, conducted at ... Health and the University of British Columbia, is published today ... study is the first to examine whether both cognitive and ...
... News) -- About 40 percent of patients with incurable ... treatments, finds a new study. German researchers asked ... gliomas (tumors) about their use of alternative therapies. ... homeopathy, 31 percent used vitamin supplements and 29 percent ...
... Reporter , MONDAY, Dec. 13 (HealthDay News) -- Taxing ... minimal weight loss, although the revenues generated could be ... Adding to a spate of recent studies examining ... Duke-National University of Singapore (NUS) Graduate Medical School looked ...
... Expression of a toxic RNA that leads to Fragile X ... according to new research from U-M Medical School scientists., In ... Of Science Genetics, U-M,s Peter K. Todd, M.D., Ph.D., led ... toxic messenger RNA (mRNA) seen in the brains of those ...
Cached Medicine News:Health News:Unique case study on Alzheimer's disease 2Health News:Depression During Pregnancy Might Affect Baby 2Health News:Strength training for seniors provides cognitive function, economic benefits: VCH-UBC study 2Health News:Many Brain Tumor Patients Turn to Alternative Therapies 2Health News:Taxing Sodas Won't Spur Much Weight Loss, Study Says 2Health News:Taxing Sodas Won't Spur Much Weight Loss, Study Says 3Health News:U-M researchers discover way to block neurodegeneration in an adult form of Fragile X syndrome 2
(Date:11/26/2014)... 25, 2014  Breckenridge Pharmaceutical, Inc. announced today ... agreement with Pii (Pharmaceutics International, Inc.) ( ... and Pii expect to develop and commercialize several ... Pii will develop, manufacture and supply the products, ... under its own label.  The drugs, comprised of ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. ... Piper Jaffray Healthcare Conference in New York ... a.m. PDT . Dr. Helen Torley , President ... The presentation will be webcast through the "Investors" section ... recording will be made available for 90 days following the ...
(Date:11/24/2014)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today ... and update at the Piper Jaffray 26 th Annual ... Eastern Time (5:30 a.m. Pacific Time), at The New York ... A live audio webcast of the presentation will be ... www.arenapharm.com . A replay of the presentation will be ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
The 96 PW is an intelligent full microplate washer with a 96 needle wash head washing all wells simultaneously. This instrument gives high throughput and outstanding washing efficiency....
Stat Fax 2600 is fully automatic microplate washer....
... 1575 immunowash microplate washer ... needle position to perform ... maximize wash efficiency. This ... choice of wash that ...
... LMW Automated Microplate ... choice for any laboratory. ... sensor allows a precise ... residual volume, digitally controlled ...
Medicine Products: